Regeneron Pharmaceuticals Earnings
NASDAQ: REGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 12:23 PM ET
Next earnings date
Fri, Oct 30, 2026
Before market open
Fiscal period
Sep/2026
EPS estimate
$13.51
Regeneron Pharmaceuticals earnings summary
Regeneron Pharmaceuticals is scheduled to report Sep/2026 earnings on Oct 30, 2026 before the market opens, with analysts expecting EPS of $13.51. In its most recent report on Jul 30, 2026 (Q2 2026), REGN posted EPS of $12.23. Revenue for the quarter was $4.29 billion.
Quarterly EPS is down 4.5% from the same quarter a year earlier. Across the last 16 reports, REGN shares moved an average of 2.9% (in either direction) in the first trading session after results, rising 8 times and falling 8 times.
Summary generated from market data by MetaCap's automated system. Methodology
REGN earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Jul 30, 2026 | — | $12.23 | — | +2.8% |
| Apr 29, 2026 | — | $6.75 | — | +1.9% |
| Feb 4, 2026 | — | $7.78 | — | +2.2% |
| Oct 28, 2025 | — | $13.62 | — | +0.9% |
| Aug 1, 2025 | — | $12.81 | — | +0.7% |
| Apr 29, 2025 | — | $7.27 | — | -12.9% |
| Feb 5, 2025 | — | $8.12 | — | -5.1% |
| Oct 31, 2024 | — | $11.54 | — | -1.8% |
| Aug 1, 2024 | — | $12.41 | — | +4.5% |
| May 2, 2024 | — | $6.27 | — | +1.8% |
| Feb 5, 2024 | — | $10.21 | — | -0.6% |
| Nov 2, 2023 | — | $8.89 | — | -2.2% |
| Aug 3, 2023 | — | $8.50 | — | +5.3% |
| May 4, 2023 | — | $7.17 | — | -2.3% |
| Feb 6, 2023 | — | $10.48 | — | -1.2% |
| Nov 3, 2022 | — | $11.66 | — | -0.8% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.